Abstract: Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G1, G2, L, R1a, R1b, R4, R5, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: One or more electronic device may use motion and/or activity sensors to estimate a user's maximum volumetric flow of oxygen, or VO2 max. In particular, although a correlation between heart rate and VO2 max may be linear at high heart rate levels, there is not a linear correlation at lower heart rate levels. Therefore, for users without extensive workout data, the motion sensors and activity sensors may be used to determine maximum calories burned by the user, workout data, including heart rate data, and body metric data. Based on these parameters, a personalized relationship between the user's heart rate and oxygen pulse (which is a function of VO2) may be determined, even with a lack of high intensity workout data. In this way, a maximum heart rate and therefore a VO2 max value may be approximated for the user.

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The invention presents a covered cavity kiln pyrolyzer with modulated means of rotation, to promote mixing and exposure of the biomass to heat, thereby allowing complete and efficient pyrolysis of biomass therein. The invention has a portal arrangement for simultaneous entry of fuel and air alongside the exit of emissions and flames to a separate hood structure. In addition to rotational modulation for mixing, the rotational capabilities of the kiln also permit the removal of processed charcoal when the portal is turned downward. The invention also has a system of internal prongs for mixing and sifting removal of char, as well as automated fuel delivery mechanisms and a system of openings to allow insertion of pipes and sensors into the kiln for monitoring and for additional delivery of reagents for better modulation and efficiency by a user during the pyrolyzation process.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH2— or —C(O)—; R1 is —OH or —OP(O)(OH)2; L is a bond, —CH2—, or —C(O)—; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and —CH3; and n is zero, 1, or 2; provided that if X is —CH2—, then L is —CH2— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH2— or —C(O)—; R1 is —OH or —OP(O)(OH)2; L is a bond, —CH2—, or —C(O)—; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and —CH3; and n is zero, 1, or 2; provided that if X is —CH2—, then L is —CH2— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor SlP1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract: The invention presents a covered cavity kiln pyrolyzer with modulated means of rotation, to promote mixing and exposure of the biomass to heat, thereby allowing complete and efficient pyrolysis of biomass therein. The invention has a portal arrangement for simultaneous entry of fuel and air alongside the exit of emissions and flames to a separate hood structure. In addition to rotational modulation for mixing, the rotational capabilities of the kiln also permit the removal of processed charcoal when the portal is turned downward. The invention also has a system of internal prongs for mixing and sifting removal of char, as well as automated fuel delivery mechanisms and a system of openings to allow insertion of pipes and sensors into the kiln for monitoring and for additional delivery of reagents for better modulation and efficiency by a user during the pyrolyzation process.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: Y is Formula (II), or Formula (III); R1, R2, R2a, R2b, R2c, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Methods and systems disclosed herein assist users in determining when to retire from a first career and how to allocate retirement funds from the first career. The user may set retirement goals and select a retirement date for the first career. The system may estimate a retirement income for the first career. The user may indicate the payment schedule in which the user will receive the first career retirement funds. The user may provide, or the system may collect from other sources, information regarding other assets and debts associated with the user. Thereafter, the user may be provided information regarding the second career needed to meet the retirement goals and advice regarding the retirement from the first career, including the retirement payout.

Abstract: A connector for receiving flow therethrough includes a body with a seat including a keyed groove, a stab including a key, and a locking member to retain the key within the keyed groove of the seat.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: A system including a modular riser gas handling system configured to couple to and be disposed vertically below a telescoping joint, wherein the modular riser gas handling system includes a diverter assembly configured to couple to and divert a flow of material into and out of a riser, and an annular blow out preventer (BOP) assembly configured to couple to the diverter assembly.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.